Biotransformation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in peripheral human lung microsomes

Drug Metabolism and Disposition

Volumn 31, Issue 9, 2003, Pages 1134-1141

  Smith, Graeme B J ^a   Bend, John R ^b   Bedard, Leanne L ^a   Reid, Ken R ^a   Petsikas, Dimitri ^a   Massey, Thomas E ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3 PYRIDYL) 1 BUTANONE 4 CARBOXYLIC ACID; 1 AMINOBENZOTRIAZOLE; 2 BUTANONE; 4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANOL; CARBON MONOXIDE; CARBOXYLIC ACID DERIVATIVE; CYTOCHROME P450; CYTOCHROME P450 2A13; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; PROADIFEN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG;

ARTICLE; BIOTRANSFORMATION; CONTROLLED STUDY; DETOXIFICATION; DRUG ACTIVATION; DRUG HYDROXYLATION; HUMAN; HUMAN TISSUE; LUNG MICROSOME; MICROSOME; OXIDATION; PRIORITY JOURNAL;

AGED; CARCINOGENS; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; FEMALE; HUMANS; LUNG; MALE; MICROSOMES; MIDDLE AGED; NITROSAMINES; SMOKING;

EID: 0041856534     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.31.9.1134     Document Type: Article

References (39)

1. Agarwal R, Wang ZY, Bik DP, and Mukhtar H (1991) Nordihydroguaiaretic acid, an inhibitor of lipoxygenase, also inhibits cytochrome P-450-mediated monooxygenase activity in rat epidermal and hepatic microsomes. Drug Metab Dispos 19:620-624.
2. Anttila S, Hukkanen J, Hakkola J, Stjernvall T, Beaune P, Edwards RJ, Boobis AR, Pelkonen O, and Raunio H (1997) Expression and localization of CYP3A4 and CYP3A5 in human lung. Am J Respir Cell Mol Biol 16:242-249.
3. Bedard LL, Smith GBJ, Reid K, Petsikas D, and Massey TE (2002) Investigation of the role of lipoxygenase in bioactivation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in human lung. Chem Res Toxicol 15:1267-1273.
4. Botto F, Seree E, el Khyari S, Cau P, Henric A, De Meo M, Bergeron P, and Barra Y (1994) Hypomethylation and hypoexpression of human CYP2E1 gene in lung tumors. Biochem Biophys Res Commun 205:1086-1092.
5. Castonguay A, Stoner GD, Schut HAJ, and Hecht SS (1983) Metabolism of tobacco-specific N-nitrosamines by cultured human tissues. Proc Natl Acad Sci USA 80:6694-6697.
6. Code EL, Crespi CL, Penman BW, Gonzalez FJ, Chang TK, and Waxman DJ (1997) Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity and role in procarcinogen activation. Drug Metab Dispos 25:985-993.
7. De Flora S, Petruzzelli S, Camoirano A, Bennicelli C, Romano M, Rindi M, Ghelarducci L, and Giuntini C (1987) Pulmonary metabolism of mutagens and its relationship with lung cancer and smoking habits. Cancer Res 47:4740-4745.
8. 1 in human lung. Carcinogenesis 17:2487-2494.
9. Gervot L, Rochat B, Gautier JC, Bohnenstengel F, Kroemer H, de Berardinis V, Martin H, Beaune P, and de Waziers I (1999) Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics 9:295-306.
10. Harris CC, Autrup H, Connor R, Barrett LA, McDowell EM, and Trump BF (1976) Interindividual variation in binding of benzo[a]pyrene to DNA in cultured human bronchi. Science (Wash DC) 194:1067-1069.
11. Hecht SS (1998) Biochemistry, biology and carcinogenicity of tobacco-specific N-nitrosamines. Chem Res Toxicol 11:559-603.
12. Hoffmann D, Rivenson A, and Hecht SS (1996) The biological significance of tobacco-specific N-nitrosamines: smoking and adenocarcinoma of the lung. Crit Rev Toxicol 26:199-211.
13. Kim PM, DeBoni U, and Wells PG (1997) Peroxidase-dependent bioactivation and oxidation of DNA and protein in benzo[a]pyrene-initiated micronucleus formation. Free Radic Biol Med 23:579-596.
14. Koenigs LL, Peter RM, Thompson SJ, Rettie AE, and Trager WF (1997) Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen. Drug Metab Dispos 25:1407-1415.
15. Kushida H, Fujita K, Suzuki A, Yamada M, Endo T, Nohmi T, and Kamataki T (2000) Metabolic activation of N-alkylnitrosamines in genetically engineered Salmonella typhimurium expressing CYP2E1 or CYP2A6 together with human NADPH-cytochrome P450 reductase. Carcinogenesis 21:1227-1232.
16. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265-275.
17. Ludwig E, Schmid J, Beschke K, and Ebner T (1999) Activation of human cytochrome P-450 3A4-catalyzed meloxicam 5′-methylhydroxylation by quinidine and hydroquinidine in vitro. J Pharmacol Exp Ther 290:1-8.
18. Mace K, Bowman ED, Vautravers P, Shields PG, Harris CC, and Pfeifer AMA (1998) Characterization of xenobiotic-metabolizing enzyme expression in human bronchial mucosa and peripheral lung tissues. Eur J Cancer 34:914-920.
19. Maser E, Stinner B, and Atalla A (2000) Carbonyl reduction of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) by cytosolic enzymes in human liver and lung. Cancer Lett 148:135-144.
20. Mathews JM and Bend JR (1986) N-Alkylaminobenzotriazoles as inhibitors of rabbit pulmonary microsomal cytochrome P-450. Mol Pharmacol 30:25-32.
21. Mathews JM, Dostal LA, and Bend JR (1985) Inactivation of rabbit pulmonary cytochrome P-450 in microsomes and isolated perfused lungs by the suicide substrate 1-aminobenzotriazole. J Pharmacol Exp Ther 235:186-190.
22. McLemore TL, Adelberg S, Liu MC, McMahon NA, Yu SJ, and Hubbard WC (1990) Expression of CYP1A1 gene in patients with lung cancer: evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas. J Natl Cancer Inst 82:1333-1339.
23. Nakajima M, Inoue T, Shimada N, Tokudome S, Yamamoto T, and Kuroiwa Y (1998) Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes. Drug Metab Dispos 26:261-266.
24. Nakajima T, Elovaara E, Gonzalez FJ, Gelboin HV, Raunio H, Pelkonen O, Vainio H, and Aoyama T (1994) Styrene metabolism by cDNA-expressed human hepatic and pulmonary cytochromes P450. Chem Res Toxicol 7:891-896.
25. Newton DJ, Wang RW, and Lu AY (1995) Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154-158.
26. Ono S, Hatanaka T, Hotta H, Satoh T, Gonzalez FJ, and Tsutsui M (1996) Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica 26:681-693.
27. Raunio H, Rautio A, Gullsten H, and Pelkonen O (2001) Polymorphisms of CYP2A6 and its practical consequences. Br J Clin Pharmacol 52:357-363.
28. Reidy GF, Mehta I, and Murray M (1989) Inhibition of oxidative drug metabolism by orphenadrine: in vitro and in vivo evidence for isozyme-specific complexation of cytochrome P-450 and inhibition kinetics. Mol Pharmacol 35:736-743.
29. Rioux N and Castonguay A (2000) The induction of cyclooxygenase-1 by a tobacco carcinogen in U937 human macrophages is correlated to the activation of NF-kappaB. Carcinogesis 21:1745-1751.
30. Rioux N and Castonguay A (2001) 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone modulation. of cytokine release in U937 human macrophages. Cancer Immunol Immunother 49:663-670.
31. Smith GBJ, Castonguay A, Donnelly PJ, Reid KR, Petsikas D, and Massey TE (1999) Biotransformation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in freshly isolated human lung cells. Carcinogenesis 20:1809-1818.
32. Smith TJ, Guo Z, Gonzalez FJ, Guengerich FP, Stoner GD, and Yang CS (1992) Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in human lung and liver microsomes and cytochromes p-450 expressed in hepatoma cells. Cancer Res 52:1757-1763.
33. Smith TJ, Stoner GD, and Yang CS (1995) Activation of 4-(methylnitrosamino)-1-(3-pyridyl)1-butanone (NNK) in human lung microsomes by cytochromes p450, lipoxygenase and hydroperoxides. Cancer Res 55:5566-5573.
34. Smith WL and DeWitt DL (1995) Biochemistry of prostaglandin endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs. Semin Nephrol 15:179-194.
35. Su T, Bao Z, Zhang QY, Smith TJ, Hong JY, and Ding X (2000) Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res 60:5074-5079.
36. Ueng YF, Kuwabara T, Chun YJ, and Guengerich FP (1997) Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 36:370-381.
37. Van der Merwe MJ, Jenkins K, Theron E, and van der Walt BJ (1993) Interaction of the di-catechols rooperol and nordihydroguaiaretic acid with oxidative systems in the human blood. A structure-activity relationship. Biochem Pharmacol 45:303-311.
38. Zhang X, Su T, Zhang Q-Y, Gu J, Caggana M, Li H, and Ding X (2002) Genetic polymorphisms of the human CYP2A13 gene: identification of single-nucleotide polymorphisms and functional characterization of an Arg257Cys variant. J Pharmacol Exp Ther 302:416-423.
39. Zivin JA and Bartko JJ (1976) Statistics for disinterested scientists. Life Sci 18:15-26.